Cargando…
Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due t...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339379/ https://www.ncbi.nlm.nih.gov/pubmed/37455900 http://dx.doi.org/10.3389/fendo.2023.1141029 |
_version_ | 1785071831505436672 |
---|---|
author | Tremblay, Douglas Dougherty, Mikaela Mascarenhas, John Gallagher, Emily Jane |
author_facet | Tremblay, Douglas Dougherty, Mikaela Mascarenhas, John Gallagher, Emily Jane |
author_sort | Tremblay, Douglas |
collection | PubMed |
description | Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due to blocking the effects of leptin in the hypothalamus have been proposed. In order to explore the metabolic changes in ruxolitinib-treated patients with myelofibrosis, we performed a pilot study to assess the feasibility of using a portable indirect calorimeter to quantify energy expenditure before and during ruxolitinib treatment and report the results of two patients. Waist circumference increased during ruxolitinib treatment in both patients. Energy expenditure initially increased followed by a decrease and then increase again, but to levels below baseline. These results suggest that weight gain secondary to ruxolitinib may be related to changes in whole body energy expenditure. |
format | Online Article Text |
id | pubmed-10339379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103393792023-07-14 Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor Tremblay, Douglas Dougherty, Mikaela Mascarenhas, John Gallagher, Emily Jane Front Endocrinol (Lausanne) Endocrinology Weight gain is a known adverse effect of ruxolitinib, a JAK1/2 inhibitor that is the mainstay of treatment for many patients with myelofibrosis. The mechanisms behind weight increase with ruxolitinib is incompletely understood, although decreased adipose tissue lipolysis and increased appetite due to blocking the effects of leptin in the hypothalamus have been proposed. In order to explore the metabolic changes in ruxolitinib-treated patients with myelofibrosis, we performed a pilot study to assess the feasibility of using a portable indirect calorimeter to quantify energy expenditure before and during ruxolitinib treatment and report the results of two patients. Waist circumference increased during ruxolitinib treatment in both patients. Energy expenditure initially increased followed by a decrease and then increase again, but to levels below baseline. These results suggest that weight gain secondary to ruxolitinib may be related to changes in whole body energy expenditure. Frontiers Media S.A. 2023-06-29 /pmc/articles/PMC10339379/ /pubmed/37455900 http://dx.doi.org/10.3389/fendo.2023.1141029 Text en Copyright © 2023 Tremblay, Dougherty, Mascarenhas and Gallagher https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Tremblay, Douglas Dougherty, Mikaela Mascarenhas, John Gallagher, Emily Jane Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor |
title | Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor |
title_full | Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor |
title_fullStr | Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor |
title_full_unstemmed | Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor |
title_short | Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor |
title_sort | energy expenditure in myelofibrosis patients treated with a jak1/2 inhibitor |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339379/ https://www.ncbi.nlm.nih.gov/pubmed/37455900 http://dx.doi.org/10.3389/fendo.2023.1141029 |
work_keys_str_mv | AT tremblaydouglas energyexpenditureinmyelofibrosispatientstreatedwithajak12inhibitor AT doughertymikaela energyexpenditureinmyelofibrosispatientstreatedwithajak12inhibitor AT mascarenhasjohn energyexpenditureinmyelofibrosispatientstreatedwithajak12inhibitor AT gallagheremilyjane energyexpenditureinmyelofibrosispatientstreatedwithajak12inhibitor |